Korea's Hanwha Chemical Leads With Enbrel Biosimilar - BIO Korea
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Hanwha Chemical Corp. - a latecomer to the biopharma industry - is trying to carve out a share of the biosimilars market with a version of Amgen's rheumatoid arthritis blockbuster Enbrel (etandercept), which is to be sold by Merck & Co. outside of Korea